JAK抑制剂:类风湿关节炎之外免疫介导疾病的新参与者
本文综述JAK/STAT通路在多种免疫介导疾病发病中的作用,并汇总JAK抑制剂在类风湿关节炎以外疾病中的临床数据(疗效与安全性)。目前JAK抑制剂仅获批用于类风湿关节炎和银屑病关节炎,但已在其他炎症性疾病中开展2期和3期临床试验。
要点
- JAK/STAT是多种细胞因子发挥功能的主要通路,参与RA、PsA、SpA、IBD及多种皮肤病等发病。
- JAK抑制剂已超过20种,目前仅获批用于RA和PsA。
- JAK抑制剂已在RA以外的其他炎症性疾病中开展2期和3期临床试验。
核心结论
- JAK抑制剂在类风湿关节炎以外的多种免疫介导疾病中已有临床数据积累,涉及疗效与安全性。
研究设计与样本
- 本文为综述,汇总JAK抑制剂在类风湿关节炎以外免疫介导疾病中可获得的临床数据,包括疗效与安全性。
主要发现
- JAK/STAT通路是多种细胞因子整合功能的主要通路之一,在RA、PsA、SpA、IBD、皮肤病(如斑秃、特应性皮炎)及干扰素病等单基因病的发病中起关键作用。
- JAK抑制剂通过阻断一个或多个JAK发挥作用,近十年已开发出超过20种成员。
- 目前JAK抑制剂仅获批用于RA和PsA,但已在其他炎症性疾病中开展2期和3期临床试验。
临床怎么用
- 风湿免疫科医生应关注JAK抑制剂在RA和PsA以外适应症中的临床试验证据,为超适应症使用提供参考。
局限性
- 本文为综述,未报告原始研究的具体样本量、效应值或统计学指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules associated with one of the major pathways through which many cytokines exert and integrate their function, and as such they are increasingly recognized as playing critical role in the pathogenesis subserving various immune-mediated diseases, including RA, PsA, SpAs, IBD, skin disorders (e.g. alopecia areata, atopic dermatitis), single-gene disorders like interferonopathies, and others. JAKs are the key initiating players of the JAK/STAT pathway. Upon binding of their respective effector molecules (cytokines, IFNs, growth factors and others) to type I and type II receptors, JAKs are activated, and through phosphorylation of themselves and of other molecules (including STATs), they mediate signal transduction to the nucleus. A class of drugs-called JAK inhibitors or JAKinibs-that block one or more JAKs has been developed in the last decade, and now numbers >20 members. Although, so far, JAK inhibitors have been marketed only for RA and PsA, these drugs have been tested in phase 2 and phase 3 clinical trials for other inflammatory conditions and beyond. In this review, we summarize the clinical data, including efficacy and safety, available for JAK inhibitors used in some immune-mediated conditions other than RA.
引用
- Fragoulis GE, McInnes IB, Siebert S, et al. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 30806709. doi:10.1093/rheumatology/key276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。